Aktis Oncology director exercises and sells stock
Aktis Oncology, Inc. director Ken Herrmann reported a same-day option exercise and sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aktis Oncology, Inc. director Ken Herrmann reported a same-day option exercise and sale. He exercised 3,065 stock options at $0.0800 per share into 3,065 shares of common stock, then sold 3,065 shares at a weighted average price of $25.2067, with individual trades between $25.00 and $25.4950. The exercised options were fully vested, and 3,506 options from this award remained outstanding, expiring November 23, 2030.
Insider Trade Summary
Exercise and Sale: 3,065 shares ($77K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Herrmann Ken
Role
Director
Sold
3,065 shs ($77K)
Approx. gross sale proceeds
$77K
Approx. exercise cost
$245.20
Approx. pre-tax spread
$77K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 3,065 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,065 | $0.08 | $245.20 |
| Sale | Common Stock F1 | 3,065 | $25.2067 | $77K |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,506 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.4950, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2. These options have vested in full.
Key Figures
Options exercised: 3,065 shares
Option exercise price: $0.0800 per share
Shares sold: 3,065 shares
+4 more
7 metrics
Options exercised
3,065 shares
Stock options exercised into common stock on July 17, 2026
Option exercise price
$0.0800 per share
Exercise price for the 3,065 stock options converted to common stock
Shares sold
3,065 shares
Common stock sold on July 17, 2026 following option exercise
Weighted average sale price
$25.2067 per share
Average price for 3,065 common shares sold in multiple transactions
Sale price range
$25.00–$25.4950 per share
Range of individual trade prices for the 3,065 shares sold
Remaining options after transaction
3,506 options
Stock options beneficially owned following the reported exercise
Option expiration date
November 23, 2030
Expiration date for the stock option award involved in the exercise
Key Terms
Stock Option (Right to Buy), weighted average price, derivative security, derivative exercise/conversion
4 terms
Stock Option (Right to Buy) financial
"security_title is reported as Stock Option (Right to Buy)"
weighted average price financial
"The price reported is a weighted average price. These shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description states Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
derivative exercise/conversion financial
"transaction_action is listed as derivative exercise/conversion"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Ken Herrmann report for AKTS?
Director Ken Herrmann reported a same-day option exercise and sale involving 3,065 Aktis Oncology, Inc. (AKTS) shares. He exercised stock options at $0.0800 per share into 3,065 common shares and then sold all 3,065 shares at a weighted average price of $25.2067.
What was the exercise price and size of Ken Herrmann’s AKTS option exercise?
Herrmann exercised 3,065 stock options for Aktis Oncology common stock at an exercise price of $0.0800 per share. These options were fully vested at the time of exercise, and the exercise generated 3,065 common shares that were then sold the same day.
When do Ken Herrmann’s remaining Aktis Oncology stock options expire?
After the reported transaction, Herrmann held 3,506 stock options from this award, which expire on November 23, 2030. The Form 4 shows this remaining derivative position as of the transaction date following the 3,065-option exercise.
Was Ken Herrmann’s AKTS trade reported under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not describe any trading plan. Based on this disclosure, the reported 3,065-share sale is not identified as occurring under a Rule 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates